Heart Failure Hf clinical trials

Explore recruiting heart failure hf clinical trials.

Recruiting heart failure hf studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart Failure Hf trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EASi-HF Reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%

Hungary, Slovakia, Czechia, Belgium, Italy, Bulgaria +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

EASi-HF Preserved – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%

Netherlands, Italy, Romania, Poland, Germany, Belgium +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Denmark, Belgium, Italy, Sweden, Czechia, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction SPIRRIT-HFpEF

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Sweden, Spain, Hungary, Italy, Denmark, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Heart Failure Hf trials by city

Heart Failure Hf in Toronto Heart Failure Hf in Vancouver Heart Failure Hf in Montreal Heart Failure Hf in Calgary Heart Failure Hf in Edmonton Heart Failure Hf in Ottawa Heart Failure Hf in Winnipeg Heart Failure Hf in Quebec City Heart Failure Hf in Hamilton Heart Failure Hf in Kitchener Heart Failure Hf in London Heart Failure Hf in Halifax Heart Failure Hf in New York Heart Failure Hf in Los Angeles Heart Failure Hf in Chicago Heart Failure Hf in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease